Sydney, Feb 26, 2026, 17:24 AEDT — After-hours.
- CSL edged up on Thursday, yet the stock remains close to the bottom of its 12-month range.
- The company continued its on-market share buybacks, according to the daily filing.
- Focus shifts to Friday’s session, with traders eyeing the March ex-dividend schedule.
CSL Ltd (CSL.AX) edged 0.6% higher to finish at A$146.02 on Thursday, bouncing between A$145.18 and A$147.15 during the session. The stock remains just above its 52-week low of A$144.61, well off the A$275.79 high. (Investing.com)
Why does it matter? CSL acts as a barometer for Australian healthcare names. A stable CSL eases some of the strain on the market’s big players. If CSL drops, though, the drag usually follows.
The buyback looms large at the moment. Investors are tracking if the company continues to scoop up shares at these prices—and if new buyers step in once that cushion disappears.
CSL said in an ASX filing dated Feb. 26 that it snapped up 79,031 shares on Wednesday, shelling out about A$11.5 million with prices spanning A$144.64 to A$146.47 apiece. Since launching its on-market buyback on Sept. 4, the company has now repurchased around 3.70 million shares, totaling roughly A$690 million, with UBS Securities Australia behind the trades. The buyback program runs until June 30 and could reach up to US$750 million. (CSL Limited)
CSL’s latest disclosure reveals it scooped up 83,519 shares on Tuesday, spending around A$12.2 million. The buyback prices landed between A$145.00 and A$148.29. (CSL Limited)
The S&P/ASX 200 climbed 0.51% on Thursday, setting another record high. Telix Pharmaceuticals and Ramsay Health Care led the charge, spotlighting the speed of capital shifting into healthcare. CSL remained volatile. (Investing.com)
But buybacks aren’t going to fix the operational issues that sent CSL sliding this month. On Feb. 11, the company’s half-year results showed underlying NPATA dropped 7%. CSL also flagged roughly US$1.1 billion in after-tax impairments and highlighted headwinds from Chinese policy changes and U.S. plasma reforms. CFO Ken Lim didn’t mince words, saying CSL was “clearly not satisfied” with its first-half performance, though the company left its full-year guidance unchanged on a constant-currency basis, stripping out FX moves. (CSL Limited)
Next session — and heading into next week — traders are eyeing the A$145 mark for a break higher, watching for evidence of buyers stepping in independently of the company’s own bid. A real move is more likely if there’s fresh detail on volumes, pricing, or cost-cutting, rather than anything coming out of the daily buyback disclosures.
Looking ahead, CSL’s interim dividend looms: shares go ex-dividend on March 10, so only holders as of that date will miss out on the payment. The record date lands on March 11, with the cash hitting accounts by April 9. Details on the Australian-dollar equivalent of the US$1.30 dividend per share are slated for release March 13, CSL said. (CSL Limited)
